This 15-amino acid peptide, originally isolated from gastric juice, promotes angiogenesis and accelerates wound healing through multiple pathways
"Double-blind" means neither patients nor doctors know who is in which group eliminating both placebo effects and evaluator bias
*Correspondence: Xiaoyun Lu, [email protected] This article was submitted to Neuroenergetics, Nutrition and Brain Health, a section of the journal Frontiers in Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Figure 1: Changes in body weight from baseline to the end of treatment at week 26 associated with the trial product estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
For Laboratory Professional Use Only
doi: 10.1073/pnas.1902179116 173